Deals and Financings • Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia; • Zhiyun Health, an online health company focused on diabetes management, raised $142 million in a combined C+ and D round; • IOVaxis Therapeutics of Nantong optioned China rights for two Targovax mutant RAS therapeutic vaccines in a $103 million deal; • Transcenta Holding of Suzhou completed a $100 million Series B+ financing to support its 10 innovative molecules in oncology, bone disorders and nephrology; • Adagene, a Suzhou immunotherapy company, raised $69 million in a Series D financing, including $50 million from lead investor General Atlantic; • Nanjing's ASK Pharm announced a $51 million agreement to acquire greater China rights to a treatment for iron deficiency from Shield Therapeutics of the UK; • 3D Med Diagnosis of Shanghai, a recent diagnostics spin-off from 3D Medicines, raised $40 million in its debut funding for early-stage cancer detection and precision medicine diagnosis; • RootPath, a Cambridge, MA biotech with two R&D sites in China, closed an $11 million Series A round to develop personalized tumor-reactive T cell receptor drugs for solid tumor cancers; • CarrierGene Biotech, a Suzhou company developing reproductive diagnostic tests, has merged with NuProbe Global of Cambridge, MA, a novel diagnostics company; Trials and Approvals • Bio-Thera Solutions of Guangzhou reported its Humira® (adalimumab) biosimilar was approved for China use; • Shanghai's Zai Lab began enrolling gastric cancer patients in a China Phase II trial of Optune®, its Tumor Treating Fields device; • Suzhou Innovent Bio will test a combination of its approved anti-PD-1, Tyvyt®, with Sirnaomics' lead RNAi candidate to treat solid tumor cancers; • Gracell Biotech of Suzhou started a clinical trial of a therapy that uses its off-the-shelf TruUCAR™ CAR-T technology for leukemia; • CStone Pharma of Suzhou and Boston's Blueprint Medicines (NSDQ: BPMC) started a China Phase Ib/II trial that combines a precision therapy with an immunotherapy for hepatocellular carcinoma; • Yisheng Biopharma of Beijing announced a collaboration with Maryland's Tavotek Bio to develop novel multi-specific immunotherapy candidates. Stock Symbols: (NSDQ: GLYC) (OSE: TRVX) (SHZ: 002755) (LSE: STX) (NSDQ: ZLAB) (HK: 01801) (HK: 2616) Share this with colleagues: // //